Use of kinase inhibitors
AssigneeBergenbio AS
InventorDavid Robert Micklem
Life of this patent
Estimating the term…
Abstract
The invention provides a compound for use for treating, preventing or managing a condition associated with the activation, mutation and/or over-expression of one or more kinases, wherein if the condition is associated with Axl over-expression, it is also associated with the activation, mutation and/or over-expression of one or more other kinases, and wherein the compound has a structure according to formula (I) : wherein the symbols used in formula (I) are as defined herein.
Claims8
A method for reducing the activity of one or more mutant kinases selected from those which are encoded by the genes ABL 1(T315I), ABL 1(Q252H), ABL1(H396P), ABL1(Y253F), ABL1(M351T), ABL1(E255K), KIT(A829P), KIT(D816H), KIT(V560G), KIT(D816V), KIT(V654A), FLT3(D835Y), FLT3(D835H), FLT3(K663Q), FLT3(N841I), RET(V804L), RET(V804M), RET(M918T), TEK(Y897S), and TEK(R849W), the method comprising contacting the kinase with an inhibitory amount of a compound selected from the group consisting of:
- 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine;
- and
- 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-((7-(S)-pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5-diamine.
Dependencies are inferred from the claim text.